经济观察网华康股份（605077）近期终止重大资产重组，实控人减持可转债，前三季度营收增长但净利 润下滑。 近期事件 机构持仓分析 机构持仓显示，截至2025年9月30日，华夏卓越成长混合A新进成为第八大流通股东，持股415.33万股。 此外，公司"华康转债"转股进展缓慢，截至2025年12月31日，累计转股比例仅0.0157%。 公司于2025年11月28日终止了发行股份及支付现金购买河南豫鑫糖醇有限公司100%股权的重大资产重 组事项，终止原因为市场环境较筹划初期发生较大变化。该事项的独立财务顾问为东方证券股份有限公 司，标的资产交易价格原定为10.98亿元。 以上内容基于公开资料整理，不构成投资建议。 公司状况 华康股份2025年前三季度实现营业收入29.59亿元，同比增长40.52%，但归母净利润1.68亿元，同比减 少9.91%。 股票近期走势 股价表现上，截至2026年2月2日，公司股价报15.84元/股，今年以来上涨7.17%，近60日下跌6.05%，当 日主力资金净流入76.42万元。 2026年1月期间，公司实际控制人及其一致行动人通过减持可转债导致合并权益比例由27.40%下降至 26.3 ...

证券代码：605077 证券简称：华康股份 公告编号：2026-008 债券代码：111018 债券简称：华康转债 浙江华康药业股份有限公司 关于注销向不特定对象发行可转换公司债券 募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、2023年向不特定对象发行可转换公司债券募集资金基本情况 根据中国证券监督管理委员会《关于同意浙江华康药业股份有限公司向不特定对象发行可转换公司债券 注册的批复》（证监许可〔2023〕2739号），本公司由主承销商东方证券承销保荐有限公司向不特定对 象发行可转换公司债券13,030,230张，每张面值为人民币100.00元，按面值发行，发行总额为人民币 130,302.30万元，共计募集资金130,302.30万元，扣除本次发行费用963.77万元后，公司本次募集资金净 额为129,338.53万元。上述募集资金到位情况业经天健会计师事务所（特殊普通合伙）验证，并由其出 具《验资报告》（天健验〔2023〕755号）。 二、2023年向不特定对象发行可转换公司债券募集资 ...

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. announced the early repurchase of shares involved in stock pledge repurchase transactions by certain controlling shareholders and their concerted actors, indicating a significant reduction in pledged shares and potential positive implications for shareholder confidence and company stability [1][6]. Group 1: Stock Pledge Repurchase - The controlling shareholders, Cheng Xinping, Xu Xiaorong, and Yu Jianming, repurchased a total of 25,500,000 shares, which accounts for 8.41% of the company's total share capital [1]. - The repurchased shares do not have any subsequent pledge plans, and the company will fulfill its information disclosure obligations if there are any future pledges [1]. Group 2: Shareholder Pledge Situation - As of the announcement date, the cumulative pledged shares by controlling shareholders and their concerted actions are detailed, indicating ongoing monitoring of shareholder equity [2]. Group 3: Convertible Bond Reduction - From January 1 to January 9, 2026, the actual controllers reduced their holdings of convertible bonds by 1,663,720 units, representing 12.77% of the total issued convertible bonds [3][4]. - This reduction led to a change in the combined equity ratio of the actual controllers from 27.40% to 26.30%, a decrease of 1.10% [3][4]. - The reduction in convertible bonds does not trigger a mandatory tender offer and will not change the actual control of the company [3][5].

Investment Rating - The report assigns an "Accumulate" rating for the basic chemical industry [2] Core Insights - The report highlights the upward trend in the prices of storage chips (DRAM), which benefits upstream semiconductor materials [4] - It notes significant profit growth for New Yangfeng, with a year-on-year increase of 23.87% in net profit excluding non-recurring items [4] - Strategic collaborations, such as the one between Boyuan Co. and Dingsheng Technology, are aimed at overcoming key material bottlenecks in solid-state batteries [4] Summary by Sections Investment Recommendations - Focus on convertible bonds in the basic chemical sector, including Zhaobang Convertible Bond, Yangfeng Convertible Bond, and others [4] Market Performance - The report reviews the performance of issued convertible bonds in the basic chemical sector from December 19 to December 26, 2025, noting increases of 14.32% for Kaisheng Convertible Bond, 13.93% for Songlin Convertible Bond, and 12.31% for Zhenhua Convertible Bond, while Su Li, Qilin, and Kesi Convertible Bonds saw declines of 2.77%, 1.79%, and 0.42% respectively [5][6] Upcoming Convertible Bonds - As of December 26, 2025, several companies, including Jiangshan Co., Shuangle Co., and others, have received shareholder approval for their convertible bond proposals [4][12]

Investment Rating - The report assigns an "Overweight" rating for the basic chemical industry [1]. Core Insights - The report highlights the focus on convertible bonds in the basic chemical sector, specifically mentioning several bonds such as Qilin Convertible Bond, Zhoubang Convertible Bond, Yangfeng Convertible Bond, Miwei Convertible Bond, Huakang Convertible Bond, and Hebang Convertible Bond as key investment opportunities [3][4]. - The report notes that the prices of storage chip DRAM are continuously rising, which benefits the upstream semiconductor materials [4]. - The report provides a summary of the performance of various convertible bonds in the basic chemical sector, indicating significant price increases for some bonds, such as Songlin Convertible Bond, which rose by 19.20%, and Su Li Convertible Bond, which increased by 7.42% [5][8]. Summary by Sections Convertible Bond Performance - The report details the performance of issued convertible bonds in the basic chemical sector, with notable increases in prices for bonds like Songlin Convertible Bond (up 19.20%), Su Li Convertible Bond (up 7.42%), and Shuiyang Convertible Bond (up 5.18%) [5][8]. - Conversely, some bonds such as Xin Hua Convertible Bond, Yong 22 Convertible Bond, and Fu Xin Convertible Bond experienced declines of 1.72%, 3.33%, and 3.37% respectively [5][8]. Upcoming Convertible Bonds - As of December 23, 2025, several companies, including Jiangshan Co., Shuangle Co., and Bailong Chuangyuan, have received shareholder approval for their convertible bond proposals [9]. - The report lists companies with pending convertible bond proposals, indicating ongoing developments in the sector [9][12].

Core Points - Huakang Co., Ltd. (605077.SH) closed at 15.98 yuan, with a decline of 2.14%, currently in a broken state [1] - The company was listed on the Shanghai Stock Exchange on February 9, 2021, with an initial public offering of 29.14 million shares at a price of 51.63 yuan per share [1] - Total funds raised amounted to 1,504,498,200 yuan, with a net amount of 1,374,771,476.94 yuan [1] - The funds were intended for various projects, including the annual production of 30,000 tons of xylitol and sorbitol, a comprehensive utilization project for viscose fiber, and a functional sugar alcohol R&D center [1] Fundraising and Financials - The total issuance cost for Huakang's IPO was 12,972.67 million yuan, with underwriting and sponsorship fees of 10,389.98 million yuan [2] - The company issued 13,030,230 convertible bonds on December 25, 2023, with a total issuance amount of 130,302.30 million yuan, set to be traded on the Shanghai Stock Exchange starting January 15, 2024 [2] Dividend Distribution - The company announced a cash dividend of 0.7 yuan per share (tax included) for the 2023 fiscal year, along with a capital reserve conversion of 0.3 shares per share, with the record date on May 27, 2024 [3] - For the 2021 fiscal year, a cash dividend of 0.6 yuan per share and a capital reserve conversion of 0.4 shares per share were distributed [3] - In 2020, a cash dividend of 1 yuan per share and a capital reserve conversion of 0.4 shares per share were issued [3]

Core Viewpoint - The announcement details the adjustment of the conversion price for the company's convertible bonds due to the implementation of a profit distribution plan for the first half of 2025, resulting in a decrease in the conversion price from 16.46 CNY to 16.26 CNY per share [2][3][6]. Group 1: Conversion Price Adjustment - The initial conversion price of the "Huakang Convertible Bonds" was set at 22.66 CNY per share, which has undergone several adjustments due to various corporate actions [5]. - The conversion price was adjusted to 16.89 CNY per share on May 28, 2024, and further adjusted to 16.39 CNY on April 24, 2025, before the latest adjustment [5]. - The new conversion price of 16.26 CNY per share will take effect on September 29, 2025, following the distribution of a cash dividend of 0.2 CNY per share [3][6]. Group 2: Profit Distribution Plan - The company plans to distribute a cash dividend of 0.2 CNY per share, amounting to a total of approximately 6,060.99622 million CNY based on the total share capital of 30,304.9811 million shares [11][13]. - The profit distribution plan was approved during the second extraordinary general meeting of shareholders held on September 8, 2025 [11]. - The distribution will be executed through the Shanghai Clearing House, with specific procedures outlined for both unrestricted and restricted shareholders [14][16].

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares, based on the total share capital registered on the equity distribution date [1][2]. Summary by Sections Profit Distribution and Capital Increase Plan - As of June 30, 2025, the company has a distributable profit of 1,174.4735 million yuan [1]. - The proposed cash dividend distribution is based on the total share capital as of the equity distribution registration date, which is 30,304.9751 million shares as of August 20, 2025 [1]. - The cash dividend represents 45.33% of the company's net profit attributable to shareholders, with no capital increase from reserves planned [1]. Decision-Making Process - The company held the 32nd meeting of the sixth board of directors and the 21st meeting of the sixth supervisory board on August 21, 2025, where the profit distribution proposal was approved [2]. - The supervisory board believes the profit distribution plan considers the company's operational and financial status and aligns with relevant regulations, supporting sustainable development without harming the interests of the company and investors [2]. Additional Notes - If there are changes in total share capital due to convertible bonds, share buybacks, or other factors before the equity distribution registration date, the per-share distribution ratio will remain unchanged, and the total distribution amount will be adjusted accordingly [2]. - The profit distribution proposal is subject to approval at the company's second extraordinary general meeting of shareholders in 2025 [2].

Core Points - The announcement details the conversion results of the "Huakang Convertible Bonds" issued by Zhejiang Huakang Pharmaceutical Co., Ltd. as of June 30, 2025 [1] Summary by Sections Convertible Bond Issuance Overview - The company issued convertible bonds on December 25, 2023, with a total scale of RMB 1,303.023 million, with a face value of RMB 100 per bond [4] - The bonds have a maturity period of up to 6 years, from December 25, 2023, to December 24, 2029, with a tiered interest rate structure [4] Conversion Status - As of June 30, 2025, a total of RMB 778,000 of the "Huakang Convertible Bonds" has been converted into company shares, representing 0.0597% of the total bond issuance [2][7] - The number of shares converted is 46,054, which is 0.0151% of the total shares outstanding before conversion [2][7] - No conversions occurred during the quarter from April 1, 2025, to June 30, 2025 [3][6] Unconverted Bonds - As of June 30, 2025, the amount of unconverted "Huakang Convertible Bonds" stands at RMB 1,302.245 million, accounting for 99.9403% of the total issuance [3][7] Share Price Adjustments - The initial conversion price was set at RMB 22.66 per share, which was adjusted to RMB 16.89 on May 28, 2024, and further adjusted to RMB 16.39 on April 24, 2025, and to RMB 16.46 on May 14, 2025, due to various corporate actions [4][5]

Core Points - The company's bond credit rating remains "AA-" and the issuer credit rating is also "AA-" with a stable outlook [1][2] - The previous ratings were confirmed with no changes in the current assessment [2] Summary by Sections Credit Rating - The previous bond credit rating was "AA-" and the issuer credit rating was "AA-" with a stable outlook [1] - The current bond credit rating is "AA-" and the issuer credit rating is "AA-" with a stable outlook, indicating no change from the previous rating [2] Rating Agency - The credit rating was conducted by Zhongzheng Pengyuan Credit Rating Co., Ltd. [2] - The comprehensive analysis and evaluation of the company's operational status were the basis for the rating [2] Reporting - The tracking credit rating report for the company's convertible bonds is available on the Shanghai Stock Exchange website [2]